Page 9 - Cardiologia Hungarica, 2022. Supplementum B – Gyógyszeres terápiák a szívelégtelenség kezelésében

Cardiologia Hungarica Tomcsányi és munkatársa: Változások az új szívelégtelenség ajánlásban –
fókuszban a mineralocorticoid-receptor-antagonisták (MRA)

A korai, kis dózisú MRA bevezetése javasolt a csök- (Eplerenone in Mild Patients Hospitalization And SurvIval Study in
kent balkamra-funkciójú szívelégtelen betegek keze- Heart Failure) J Am Coll Cardiol 2013 Oct 22; 62(17): 1585–93.
lésében. Az MRA-k közül az eplerenon a kedvezőbb https://doi.org/10.1016/j.jacc.2013.04.086
mellékhatásprofilja és kardiometabolikus hatásai miatt 9. Ahmed A, Zannad F, Love TE, et al. A propensity-matched study
előnyben részesítendő. of the association of low serum potassium levels and mortality in
chronic heart failure. Eur Heart J 2007; 28: 1334–1343.
https://doi.org/ 10.1093/eurheartj/ehm091
10. Rossignol P, Dobre D, McMurray JJV, et al. Incidence, Determi-
Irodalom nants, and Prognostic Significance of Hyperkalemia and Worsening
1. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Docu- Renal Function in Patients With Heart Failure Receiving the Minera-
ment Group. 2021 ESC Guidelines for the diagnosis and treatment locorticoid Receptor Antagonist Eplerenone or Placebo in Addition
of acute and chronic heart failure. Eur Heart J 2021 Sep 21; 42(36):
3599–3726. Erratum in: Eur Heart J 2021 Oct 14; PMID: 34447992. to Optimal Medical Therapy, Results From the Eplerenone in Mild
https://doi.org/10.1093/eurheartj/ehab368 Patients Hospitalization and Survival Study in Heart Failure (EMP-
2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines HASIS-HF), Circulation: Heart Failure 2014; 7: 51–58.
for the diagnosis and treatment of acute and chronic heart failure: https://doi.org/10.1161/CIRCHEARTFAILURE.113.000792
The Task Force for the diagnosis and treatment of acute and chronic 11. Butler J, Anker SD, Lund LH, et al. Patiromer for the manage-
heart failure of the European Society of Cardiology (ESC). Devel- ment of hyperkalemia in heart failure with reduced ejection fraction:
oped with the special contribution of the Heart Failure Association the DIAMOND trial. Eur Heart J 2022; 43: 4362–4373.
(HFA) of the ESC. Eur J Heart Fail 2016 Aug; 18(8): 891–975. Epub https://doi.org/10.1093/eurheartj/ehac401
2016 May 20. PMID: 27207191. https://doi.org/10.1002/ejhf.592 12. Ferreira JP, Zannad F, Butler J, et al. Empagliflozin and serum
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et potassium in heart failure: an analysis from EMPEROR-Pooled. Eur
al. The effect of spironolactone on morbidity and mortality in patients Heart J 2022; 43: 2984–2993.
with severe heart failure. Randomized Aldactone Evaluation Study https://doi.org/10.1093/eurheartj/ehac306
Investigators. N Engl J Med 1999; 341: 709–717. 13. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart
https://doi.org/10.1056/NEJM199909023411001 failure with reduced ejection fraction: the CHAMP-HF registry. J Am
4. Zannad F, McMurray JJ, Drexler H, et al. Rationale and design of Coll Cardiol 2018; 72: 351–366.
the Eplerenone in Mild Patients Hospitalization And SurvIval Study https://doi.org/10.1016/j.jacc.2018.04.070
in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010; 12: 617– 14. Li Shen, Singh Jhund, Docherty KF. Accelerated and personali-
622. https://doi.org/10.1093/eurjhf/hfq049 zed therapy for heart failure with reduced ejection fraction, Europe-
5. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldos- an Heart Journal 2022; 43: 2573–2587.
terone blocker, in patients with left ventricular dysfunction after myo- https://doi.org/10.1093/eurheartj/ehac210
cardial infarction. N Engl J Med 2003; 348: 1309–1321. (Erratum, N 15. Yamaji M, Tsutamoto T, Kawahara C, et al. Effect of eplereno-
Engl J Med 2003; 348: 2271.) ne versus spironolactone on cortisol and hemoglobin A1c levels in
https://doi.org/10.1056/NEJMoa030207 patients with chronic heart failure. Am Heart J 2010; 160: 915–921.
6. Pitt B, Williams G, Remme W, et al. The EPHESUS Trial: Eple- https://doi.org/10.1016/j.ahj.2010.04.024
renone in Patients with Heart Failure Due to Systolic Dysfunction
Complicating Acute Myocardial Infarction, Cardiovascular Drugs and 16. Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy
Therapy 2001; 15: 79–87. https://doi.org/10.1023/a:1011119003788 of eplerenone, enalapril, and eplerenone/enalapril combination in di-
7. Zannad F, Alla F, Dousset B, Perez A. et al. Limitation of exces- abetic hypertensives with microalbuminuria (abstract). Am J Hyper-
sive extracellular matrix turnover may contribute to survival benefit tens 2002; 15: 24A. https://doi.org/10.1016/S0895-7061(02)02333-6
of spironolactone therapy in patients with congestive heart failure: 17. Pradhan A, Vohra S, Sethi R. Eplerenone: The multifaceted drug
insights from the Randomized Aldactone Evaluation Study (RALES). in cardiovascular pharmacology, J Pharm Bioallied Sci 2020 Oct-
Circulation 2000; 102: 2700–2706. Dec; 12(4): 381–390. https://doi.org/10.4103/jpbs.JPBS_338_19
https://doi.org/10.1161/01.cir.102.22.2700 18. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart
8. Eschalier R, Mc. Murray JJ, Swedberg K, et al. Safety and efficacy failure with reduced ejection fraction: the CHAMP-HF registry. J Am
of eplerenone in patients at high risk for hyperkalemia and/or worse- Coll Cardiol 2018; 72: 351–366.
ning renal function: analyses of the EMPHASIS-HF study subgroups https://doi.org/10.1016/j.jacc.2018.04.070

B7